Drugs / MMF
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03913026 Background | Apr 2019 → Jun 2027 expected | hematopoietic and lymphoid cell neoplasm | Ciusss de L'Est de l'Île de Montréal | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMF | “standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus)” NCT03913026 ↗ |